Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  ImmuPharma PLC    IMM   GB0033711010

IMMUPHARMA PLC

(IMM)
  Report  
Delayed Quote. Delayed London Stock Exchange - 05/24 11:35:08 am
9.88 GBp   -4.26%
05/24IMMUPHARMA : Final results
PU
05/07IMMUPHARMA : Corporate Update - Replacement
PU
04/01IMMUPHARMA : Update on Nucant Cancer Programme
PU
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

ImmuPharma : dips as efforts to commercialise Lupuzor continue (IMM)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/16/2019 | 03:53am EDT

ImmuPharma (LSE:IMM) dropped 8.6pc on Thursday morning to 11.7p after revealing that attempts to get its flagship drug to market are ongoing. The firm said it is continuing to engage with potential corporate partners that can support the full release of Lupuzor, designed to treat autoimmune disease lupus, over the longer term.

The drug failed its pivotal Phase II trial last April after its superior response rate in a double-blind trial was not deemed to be statistically significant. As a result, Lupuzor failed to meet the trials endpoint, leading ImmuPharmas shares to collapse by 74.7pc. The organisation has struggled to recover since.

As well as searching for partners, the business is in final preparations for a managed access program (MAP) for the drug. The MAP, which is being funded by ImmuPharmas existing cash resources, will give up to 500 eligible patients in Europe early access to the medication for a minimum of two years, before any regulatory filings.

The programme is longer, more extensive and cheaper than the Phase III trial, which cost c.10m and was carried out on 200 patients for twelve months. It also gives ImmuPharma access to ongoing results rather than having to wait until the programme has completed.

Speaking to ValueTheMarkets last November, ImmuPharmas chairman Tim McCarthy said this real-time approach allows the firm to monitor the drugs effectiveness as the trial unfolds. From an investors standpoint, this means the company can deliver regular newsflow throughout the process. He added that the data generated from the MAP will also be an invaluable addition to the firms application for final regulatory approval:

Not only will the MAP allow us to help patients ahead of our drug being approved, it will provide us an invaluable set of data that we can put into the application for when we do go for formal approval, at some point in the future. These programmes are becoming increasingly common. Out of the top 20 pharma companies globally, 18 are using MAP on a regular basis to supplement clinical trial data.

In Thursdays release, ImmuPharma said further MAP updates will be provided in due course.

Alongside the MAP, ImmuPharma is carrying out a six-month follow-up study, permitting patients from the completed phase III study to continue receiving the drug. On Thursday, it said it was on track to release the results of this in Q2 2019.

Elsewhere, the firm said that discussions are continuing on a clinical development collaboration for its cancer drug Nucant with a specialist oncology business called Incanthera. Nucant is planned for use in combination cancer treatments, age-related macular degeneration, and diabetic retinopathy. The medication has passed the first phase of clinical trials.

Finally, the business said it is continuing to look at ways to progress the assets owned by its Bordeaux-based subsidiary Ureka. Ureka is focusing on transforming peptides into efficient drugs for treatments in therapeutic areas including Type II diabetes and Non-Alcoholic-Steato-Hepatitis.

On Thursdays update, McCarthy said: We remain focused on creating long term value throughout our portfolio through initiatives including the Managed Access Program for Lupuzor, whilst the Company continues to engage with industry partners for potential collaboration opportunities on its projects.

(c) 2019 Future Publishing Limited Quay House, The Ambury, Bath BA1 1UA. All rights reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUPHARMA PLC
05/24IMMUPHARMA : Final results
PU
05/07IMMUPHARMA : Corporate Update - Replacement
PU
04/01IMMUPHARMA : Update on Nucant Cancer Programme
PU
03/16IMMUPHARMA : dips as efforts to commercialise Lupuzor continue (IMM)
AQ
03/14IMMUPHARMA : Corporate Update
PU
02/26IMMUPHARMA : Technology review published-Nature Communications
PU
2018IMMUPHARMA : Clinical Development Collaboration with Incanthera
PU
2018IMMUPHARMA : Appointment of Nominated Adviser
PU
2018IMMUPHARMA : Update on Corporate Activities
PU
2018IMMUPHARMA : Interim Results
PU
More news
Financials (GBP)
Sales 2019 0,10 M
EBIT 2019 -4,34 M
Net income 2019 -
Finance 2019 2,00 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales 2019 118x
Capi. / Sales 2020 138x
Capitalization 13,8 M
Chart IMMUPHARMA PLC
Duration : Period :
ImmuPharma PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUPHARMA PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Average target price 0,04  GBP
Spread / Average Target -64%
Managers
NameTitle
Dimitri F. Dimitriou Chief Executive Officer & Director
Robert Henri Zimmer President, Director & Chief Scientific Officer
Timothy Paul McCarthy Non-Executive Chairman
Tracy Weimar Vice President-Operations & Finance, Secretary
Franco di Muzio Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUPHARMA PLC-15.91%18
GILEAD SCIENCES6.94%85 054
VERTEX PHARMACEUTICALS3.66%43 994
REGENERON PHARMACEUTICALS-16.32%33 671
GENMAB14.61%11 324
SAREPTA THERAPEUTICS INC10.73%8 961